M C Shibata1, R T Tsuyuki, N Wiebe. 1. Epicore Centre, Division of Cardiology, University of Alberta, AB, Canada. marcelo.shibata@ualberta.ca
Abstract
BACKGROUND: Trials evaluating angiotensin-receptor blockers in heart failure (HF) have shown inconsistent results. OBJECTIVE: To evaluate the effect of angiotensin II (AII) receptor blockers in HF patients on total mortality and HF hospitalisations. METHODS: Systematic search of the literature through MEDLINE (1980-2007) and abstracts of major cardiovascular congresses from 2002 to 2007. ELIGIBILITY CRITERIA: (i) randomised controlled trials with more than 500 patients and follow up > 6 months, (ii) availability of total mortality and/or (iii) availability of hospital admission because of worsening HF. Data retrieved by two independent reviewers. DerSimonian random effects model was used. RESULTS: Mortality data were available from 27,495 patients. When AII receptor blockers plus angiotensin-converting enzyme inhibitors (ACE-I) were compared with ACE-I in chronic HF trials, the relative risk (RR) for death was 0.98 (95% CI: 0.84-1.15). When AII receptor blockers were compared with ACE-I the RR for death was 1.06 (95% CI: 0.56-1.62). Similar results were found for postmyocardial infarction trials. The effects on hospital admission revealed a RR of 0.83 (95% CI: 0.71-0.97) and 1.09 (95% CI: 0.74-1.60) respectively. CONCLUSION: Angiotensin II receptor blockers did not show any beneficial effect on mortality when used in combination with ACE-I or when compared with ACE-I alone. A 17% reduction in hospital admissions was observed.
BACKGROUND: Trials evaluating angiotensin-receptor blockers in heart failure (HF) have shown inconsistent results. OBJECTIVE: To evaluate the effect of angiotensin II (AII) receptor blockers in HF patients on total mortality and HF hospitalisations. METHODS: Systematic search of the literature through MEDLINE (1980-2007) and abstracts of major cardiovascular congresses from 2002 to 2007. ELIGIBILITY CRITERIA: (i) randomised controlled trials with more than 500 patients and follow up > 6 months, (ii) availability of total mortality and/or (iii) availability of hospital admission because of worsening HF. Data retrieved by two independent reviewers. DerSimonian random effects model was used. RESULTS: Mortality data were available from 27,495 patients. When AII receptor blockers plus angiotensin-converting enzyme inhibitors (ACE-I) were compared with ACE-I in chronic HF trials, the relative risk (RR) for death was 0.98 (95% CI: 0.84-1.15). When AII receptor blockers were compared with ACE-I the RR for death was 1.06 (95% CI: 0.56-1.62). Similar results were found for postmyocardial infarction trials. The effects on hospital admission revealed a RR of 0.83 (95% CI: 0.71-0.97) and 1.09 (95% CI: 0.74-1.60) respectively. CONCLUSION: Angiotensin II receptor blockers did not show any beneficial effect on mortality when used in combination with ACE-I or when compared with ACE-I alone. A 17% reduction in hospital admissions was observed.
Authors: Shelby D Reed; Matthew P Neilson; Matthew Gardner; Yanhong Li; Andrew H Briggs; Daniel E Polsky; Felicia L Graham; Margaret T Bowers; Sara C Paul; Bradi B Granger; Kevin A Schulman; David J Whellan; Barbara Riegel; Wayne C Levy Journal: Am Heart J Date: 2015-08-20 Impact factor: 4.749
Authors: Pablo Pazos-López; Jesús Peteiro-Vázquez; Ana Carcía-Campos; Lourdes García-Bueno; Juan Pablo Abugattas de Torres; Alfonso Castro-Beiras Journal: Vasc Health Risk Manag Date: 2011-04-04
Authors: Hisham Dokainish; Lauren Jewett; Robby Nieuwlaat; Joshua Coulson; Catherine Demers; Eva Lonn; Jeff Healey; Brian Haynes; Stuart Connolly Journal: Open Cardiovasc Med J Date: 2014-09-30
Authors: Pupalan Iyngkaran; Danny Liew; Peter McDonald; Merlin C Thomas; Christopher Reid; Derek Chew; David L Hare Journal: Curr Cardiol Rev Date: 2016